Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
CRISPR Therapeutics AG - Common Shares
(NQ:
CRSP
)
57.99
-0.20 (-0.34%)
Streaming Delayed Price
Updated: 4:00 PM EST, Jan 7, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about CRISPR Therapeutics AG - Common Shares
< Previous
1
2
...
24
25
26
27
28
29
30
31
32
...
34
35
Next >
Where Will Editas Medicine Be in 1 Year?
↗
November 20, 2022
The company could continue lagging the market for a while.
Via
The Motley Fool
2 Growth Stocks That Could Double in 2023
↗
November 17, 2022
Both are lagging the market this year.
Via
The Motley Fool
Crispr Therapeutics Stock: Bull vs. Bear
↗
November 15, 2022
Crispr shares have fallen about 20% so far this year.
Via
The Motley Fool
5 Top Stocks to Buy Before 2023
↗
November 15, 2022
These stocks have what it takes to win over time.
Via
The Motley Fool
Vertex Pharmaceuticals: Buy at the High?
↗
November 14, 2022
Vertex is submitting a potential blockbuster to regulators this month.
Via
The Motley Fool
Want $1 Million in Retirement? Invest $100,000 in These 3 Stocks and Wait a Decade
↗
November 12, 2022
These top stocks could be wise additions to a well-rounded investment portfolio.
Via
The Motley Fool
Why Shares of CRISPR Therapeutics Dropped 19.9% in October
↗
November 07, 2022
Several factors weighed on the gene-editing biotech stocks last month.
Via
The Motley Fool
Where CRISPR Therapeutics Stands With Analysts
↗
November 02, 2022
CRISPR Therapeutics (NASDAQ:CRSP) has observed the following analyst ratings within the last quarter:
Via
Benzinga
3 Top Healthcare Stocks Defying the Bear Market
↗
November 10, 2022
These healthcare companies haven't been slowed by macroeconomic conditions.
Via
The Motley Fool
$100 Invested In This Stock 5 Years Ago Would Be Worth $300 Today
↗
November 09, 2022
CRISPR Therapeutics (NASDAQ:CRSP) has outperformed the market over the past 5 years by 15.41% on an annualized basis producing an average annual return of 23.37%. Currently, CRISPR Therapeutics has a...
Via
Benzinga
3 Healthcare Stocks That Could Go Parabolic
↗
November 09, 2022
These beaten-down stocks are ready for a rebound.
Via
The Motley Fool
Got $1,000? 2 Smart Stocks to Consider Buying Right Now
↗
November 06, 2022
Don't overlook these major healthcare names on your next stock-buying spree.
Via
The Motley Fool
2 Biotech Stocks That Could Make You Richer
↗
November 04, 2022
Both drugmakers are pretty close to their 52-week highs, but that shouldn't stop investors.
Via
The Motley Fool
3 Top Healthcare Stocks to Buy for November
↗
November 04, 2022
Catalysts lie ahead for these promising stocks.
Via
The Motley Fool
What 8 Analyst Ratings Have To Say About CRISPR Therapeutics
↗
November 02, 2022
Within the last quarter, CRISPR Therapeutics (NASDAQ:CRSP) has observed the following analyst ratings:
Via
Benzinga
Expert Ratings for CRISPR Therapeutics
↗
November 02, 2022
Over the past 3 months, 8 analysts have published their opinion on CRISPR Therapeutics (NASDAQ:CRSP) stock. These analysts are typically employed by large Wall Street banks and tasked with...
Via
Benzinga
Better Buy: CRISPR Therapeutics vs. Bluebird Bio
↗
October 27, 2022
These two companies have performed almost equally poorly on the stock market in the past year.
Via
The Motley Fool
2 Monster Stocks to Buy Without Any Hesitation
↗
October 26, 2022
These stocks are crushing the bear market.
Via
The Motley Fool
Here's How Much $100 Invested In CRISPR Therapeutics 5 Years Ago Would Be Worth Today
↗
October 24, 2022
CRISPR Therapeutics (NASDAQ:CRSP) has outperformed the market over the past 5 years by 13.48% on an annualized basis producing an average annual return of 21.37%. Currently, CRISPR Therapeutics has a...
Via
Benzinga
S&P 500 Biotech Giant Vertex Leads 5 Stocks Showing Strength
↗
October 22, 2022
Vertex and LNG play Cheniere Energy are setting up bullishly.
Via
Investor's Business Daily
The Top 5 Stocks Cathie Wood Bought and Sold This Week
↗
October 21, 2022
Cathie Wood's flagship ETF, the ARK Innovation ETF, hit a five-year and 52-week low this week, casting doubts on the investment manager.
Via
InvestorPlace
2 Budding Growth Stocks That Could Turn $1,000 Into $10,000 in 8 Years
↗
October 21, 2022
They're both using unique and highly efficient approaches to developing and deploying their medicines.
Via
The Motley Fool
CRISPR Stocks: Will Concerns Over Risk Inhibit Gene-Editing Cures?
↗
October 20, 2022
Despite enthusiasm in some camps, the risk of potential cures clouds market projections.
Via
Investor's Business Daily
2 Under-the-Radar Biotech Stocks to Buy in 2022
↗
October 19, 2022
These two drugmakers are growing in prominence.
Via
The Motley Fool
3 Cathie Wood Stocks to Buy and Hold for 10 Years
↗
October 19, 2022
The risks are formidable, but the chances of a massive gain are too much to pass up.
Via
The Motley Fool
2 Top Healthcare Stocks to Buy for the Long Haul
↗
October 18, 2022
These biotech companies have a long ramp of revenue growth ahead.
Via
The Motley Fool
My Best Stocks to Buy Now and Hold Forever
↗
October 14, 2022
These are ideal "forever" stocks.
Via
The Motley Fool
Missed Out On Axsome Therapeutics? My Best Biotech Stock to Buy and Hold
↗
October 12, 2022
Vertex already generates billions in revenue -- but there may be more to come.
Via
The Motley Fool
What 7 Analyst Ratings Have To Say About CRISPR Therapeutics
↗
October 11, 2022
Analysts have provided the following ratings for CRISPR Therapeutics (NASDAQ:CRSP) within the last quarter:
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For October 11, 2022
↗
October 11, 2022
Upgrades
Via
Benzinga
< Previous
1
2
...
24
25
26
27
28
29
30
31
32
...
34
35
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
